Organon & Co. filed a Form 8-K on July 31, 2026, to furnish supplemental non-GAAP financial metrics for the quarter ended June 30, 2026, in lieu of a standard earnings press release due to its pending merger with Sun Pharmaceutical Industries Limited. The company reported Adjusted EBITDA of $461 million and Adjusted Net Income of $230 million for the three-month period. GAAP diluted EPS was $0.40 compared to an Adjusted Diluted EPS of $0.85. Organon & Co. operates in the pharmaceutical industry, focusing on consumer health and specialty medicines.
